Ubs Group Ag Verona Pharma PLC Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Verona Pharma PLC stock. As of the latest transaction made, Ubs Group Ag holds 1,186,181 shares of VRNA stock, worth $125 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,186,181

Previous 262,854 351.27%

Holding current value

$125 Million

Previous $16.7 Million 572.27%

% of portfolio

0.02%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$53.9 - $98.68 $49.8 Million - $91.1 Million	923,327 Added 351.27%	1,186,181 $112 Million
Q1 2025 May 13, 2025	SELL	$44.81 - $69.63 $4.95 Million - $7.7 Million	-110,551 Reduced 29.61%	262,854 $16.7 Million
Q4 2024 Feb 14, 2025	BUY	$28.71 - $47.02 $6.86 Million - $11.2 Million	238,837 Added 177.48%	373,405 $17.3 Million
Q3 2024 Nov 14, 2024	BUY	$15.46 - $30.16 $489,911 - $955,740	31,689 Added 30.8%	134,568 $3.87 Million
Q2 2024 Aug 13, 2024	BUY	$11.48 - $17.02 $1.16 Million - $1.72 Million	101,044 Added 5506.49%	102,879 $1.49 Million
Q1 2024 May 13, 2024	SELL	$15.3 - $20.24 $2,738 - $3,622	-179 Reduced 8.89%	1,835 $29,000
Q4 2023 Feb 09, 2024	SELL	$11.94 - $20.47 $15,796 - $27,081	-1,323 Reduced 39.65%	2,014 $40,000
Q3 2023 Nov 09, 2023	BUY	$16.3 - $22.09 $5,411 - $7,333	332 Added 11.05%	3,337 $54,000
Q2 2023 Aug 11, 2023	SELL	$19.41 - $23.43 $47,108 - $56,864	-2,427 Reduced 44.68%	3,005 $63,000
Q1 2023 May 12, 2023	BUY	$18.06 - $25.27 $22,809 - $31,916	1,263 Added 30.3%	5,432 $109,000
Q4 2022 Feb 08, 2023	BUY	$9.84 - $26.13 $33,367 - $88,606	3,391 Added 435.86%	4,169 $108,000
Q3 2022 Nov 10, 2022	BUY	$4.14 - $13.59 $3,220 - $10,573	778 New	778 $8,000
Q2 2022 Aug 10, 2022	SELL	$3.55 - $5.06 $2,325 - $3,314	-655 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.82 - $6.98 $3,157 - $4,571	655 New	655 $3,000
Q4 2021 Feb 14, 2022	SELL	$3.91 - $7.08 $3,436 - $6,223	-879 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.29 - $6.35 $4,649 - $5,581	879 New	879 $5,000
Q2 2021 Aug 13, 2021	SELL	$5.72 - $9.09 $8,048 - $12,789	-1,407 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$7.08 - $9.33 $2,237 - $2,948	-316 Reduced 18.34%	1,407 $12,000
Q4 2020 Feb 11, 2021	BUY	$5.51 - $8.11 $1,801 - $2,651	327 Added 23.42%	1,723 $12,000
Q3 2020 Nov 12, 2020	BUY	$4.45 - $10.2 $6,212 - $14,239	1,396 New	1,396 $9,000
Q2 2020 Jul 31, 2020	SELL	$3.6 - $6.12 $14,400 - $24,480	-4,000 Closed	0 $0
Q1 2020 May 01, 2020	SELL	$2.16 - $7.28 $13,078 - $44,080	-6,055 Reduced 60.22%	4,000 $16,000
Q4 2019 Feb 14, 2020	BUY	$3.7 - $6.58 $33,078 - $58,825	8,940 Added 801.79%	10,055 $58,000
Q3 2019 Nov 14, 2019	SELL	$4.03 - $5.44 $1,096 - $1,479	-272 Reduced 19.61%	1,115 $5,000
Q2 2019 Aug 14, 2019	BUY	$5.1 - $6.91 $7,073 - $9,584	1,387 New	1,387 $7,000
Q1 2019 May 14, 2019	SELL	$5.52 - $10.0 $761 - $1,380	-138 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$9.0 - $13.47 $1,242 - $1,858	138 New	138 $1,000
Q2 2018 Aug 14, 2018	SELL	$13.66 - $21.0 $9,602 - $14,763	-703 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$11.69 - $20.97 $8,206 - $14,720	702 Added 70200.0%	703 $14,000
Q4 2017 Feb 14, 2018	BUY	$10.8 - $15.75 $10 - $15	1	1 $0

Others Institutions Holding VRNA

# of Institutions

322

Shares Held

76.8M

Call Options Held

970K

Put Options Held

3.13M

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $6.41B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account